ABSTRACT
We report a 54‐year‐old woman with stable angina who exhibited heterogeneous responses of tandem left anterior descending artery (LAD) plaques to intensive lipid‐lowering therapy. Coronary CT angiography performed at another hospital suggested diffuse disease, and she presented to our clinic for a second opinion. Intravascular ultrasound revealed a lipid‐rich proximal LAD lesion and a fibrous‐predominant distal lesion, along with a smaller intermediate lesion. Fractional flow reserve (FFR) pullback showed distal LAD FFR of 0.50, increasing to 0.73 across the distal lesion (ΔFFR + 0.23) and to 0.95 across the proximal lesion (ΔFFR + 0.22). Although PCI was considered, in accordance with the patient's preference and guideline recommendations, medical therapy with high‐intensity statin, ezetimibe, aspirin, nebivolol, and isosorbide dinitrate was initiated. LDL‐C decreased to < 35 mg/dL and remained consistently suppressed. After 2 years, serial CT and intravascular ultrasound (IVUS) demonstrated near‐complete regression of the lipid‐rich proximal lesion with lumen enlargement, a marked reduction in IVUS features consistent with a lipid‐rich core, and attenuation of its lesion‐specific physiological contribution (ΔFFR + 0.02), whereas the distal fibrous lesion remained stable (ΔFFR + 0.20) (lesion‐specific functional improvement defined as attenuation of lesion‐specific ΔFFR contribution on FFR pullback). The intermediate lesion also regressed morphologically, although it was not assessed functionally. The patient remained asymptomatic with preserved exercise capacity. This case suggests that plaque morphology may influence the response to lipid‐lowering therapy and highlights the value of multimodality imaging with lesion‐specific physiological assessment in individualized management of stable coronary disease.
Keywords: fractional flow reserve, intravascular ultrasound, lipid‐lowering therapy, plaque regression, stable angina
1. Introduction
We describe a case of stable angina in which tandem LAD plaques exhibited strikingly different responses to medical therapy, underscoring the role of multimodality imaging in guiding individualized treatment. Coronary atherosclerosis is a heterogeneous disease in which plaque morphology is a critical determinant of vulnerability and therapeutic response. Lipid‐rich thin‐cap fibroatheromas are prone to rupture and acute coronary syndromes, whereas fibrous‐predominant lesions are relatively stable. Intensive lipid‐lowering therapy with high‐dose statins, often combined with ezetimibe, reduces atheroma volume and promotes stabilization, but the degree of regression varies depending on plaque composition [1, 2]. While large intracoronary imaging and plaque morphology studies have demonstrated the overall benefits of intensive lipid‐lowering therapy [3, 4, 5], direct intra‐individual comparisons across different lesion types remain rare. These observations are important, as functional recovery assessed by fractional flow reserve (FFR) may be limited when fibrous‐predominant lesions persist despite regression of lipid‐rich plaques [6]. We describe a case of stable angina in which tandem LAD plaques exhibited strikingly different responses to medical therapy, underscoring the role of multimodality imaging in guiding individualized treatment.
2. Case
A 54‐year‐old woman presented with exertional chest discomfort. She had a history of hypertension and hyperlipidemia, for which medication had been prescribed, but adherence was suboptimal. She had no other cardiovascular risk factors, including diabetes mellitus, smoking, or family history of premature coronary artery disease.
Coronary CT angiography performed at another hospital revealed diffuse severe stenoses of the proximal‐to‐mid LAD, and she visited our clinic for a secondary opinion. On admission, she was hemodynamically stable, and physical examination and resting electrocardiogram were unremarkable. Laboratory results showed LDL‐C 86 mg/dL, HDL‐C 41 mg/dL, triglycerides 70 mg/dL, fasting glucose 90 mg/dL, HbA1c 5.3%, hs‐CRP 1.1 mg/L, and normal cardiac enzymes.
Repeat CT angiography at our center confirmed severe tandem LAD lesions (Figure 1A,B). Coronary angiography with FFR pullback showed a distal LAD FFR of 0.50, increasing to 0.73 across the distal lesion (ΔFFR + 0.23), and further to 0.95 across the proximal lesion (ΔFFR + 0.22) (Figure 1E). FFR was obtained with standard pressure equalization and drift checks, and pullback was performed manually at a slow, continuous pace under sustained hyperemia at both baseline and follow‐up. Hyperemia was induced using intravenous adenosine at the standard dose (140 μg/kg/min) at baseline and follow‐up, and measurements were obtained after hemodynamic stabilization with repeat equalization and post‐measurement drift checks. Intravascular ultrasound identified the proximal LAD lesion as lipid‐rich with a large necrotic core (Figure 1D), the distal lesion as fibrous‐predominant (Figure 1C), and an additional smaller intermediate lesion proximal to the distal stenosis. This intermediate lesion was not separately assessed physiologically. Quantitative IVUS planimetry (e.g., MLA, plaque burden) was not available for this case; therefore, IVUS interpretation is presented qualitatively.
FIGURE 1.

Multimodality assessment of tandem LAD lesions at baseline and follow‐up. (A, B) Coronary CT and angiography at baseline show severe tandem stenoses (arrows). (C, D) IVUS reveals lipid‐rich proximal (arrowheads) and fibrous‐predominant distal plaques (asterisks). (E) Baseline FFR pullback: distal FFR 0.50, increasing to 0.73 across the distal lesion (ΔFFR + 0.23) and to 0.95 across the proximal lesion (ΔFFR + 0.22). (A′, B′) Follow‐up CT/angiography show regression of the proximal and intermediate lesions (dotted arrows), distal lesion persistent. (C′, D′) Follow‐up IVUS: regression and calcific stabilization of proximal plaque, distal plaque unchanged. (E′) Follow‐up FFR pullback: distal FFR 0.75, increasing to 0.95 across the distal lesion (ΔFFR + 0.20) and to 0.97 across the proximal lesion (ΔFFR + 0.02). [Color figure can be viewed at wileyonlinelibrary.com]
Although PCI was considered, the patient was clinically stable without high‐risk features. At baseline, there was no left main disease, no high‐risk multivessel anatomy, and no LV systolic dysfunction (LVEF = 64%). In this context, contemporary guideline‐supported evidence supports optimized medical therapy as an appropriate initial strategy in stable coronary artery disease. Physiological assessment demonstrated distributed ischemia from tandem LAD lesions rather than a single focal stenosis suitable for straightforward revascularization. Furthermore, the presence of a lipid‐rich proximal plaque suggested a potentially favorable response to intensive lipid‐lowering therapy. Patient preference was incorporated into this shared decision‐making process. Guideline‐directed therapy was initiated with rosuvastatin 20 mg plus ezetimibe 10 mg daily, together with anti‐anginal medication consisting of aspirin 100 mg, nebivolol 2.5 mg, and isosorbide dinitrate 40 mg. Within 5 months, LDL‐C decreased to < 35 mg/dL and remained consistently suppressed throughout follow‐up (Figure 2A).
FIGURE 2.

Quantitative summary of lipid‐lowering therapy and physiological changes. (A) LDL‐C trajectory demonstrates sustained LDL‐C suppression from a baseline level of 86 mg/dL to < 35 mg/dL (> 60% reduction) throughout follow‐up under intensive statin and ezetimibe therapy. (B) Lesion‐specific ΔFFR contribution: baseline overall FFR 0.50 reflected ΔFFR + 0.23 (distal) and +0.22 (proximal). At follow‐up, overall FFR improved to 0.75, with persistent ΔFFR + 0.20 (distal) and attenuated ΔFFR + 0.02 (proximal). [Color figure can be viewed at wileyonlinelibrary.com]
Serial imaging demonstrated divergent responses. At 1 year, CT angiography showed marked regression of the proximal lesion, while the distal lesion was unchanged. At 2 years, repeat CT and IVUS confirmed near‐complete regression of the proximal lipid‐rich lesion, with a marked reduction in IVUS features consistent with a lipid‐rich core, lumen expansion, and calcific stabilization (Figure 1A′–D′). The distal fibrous lesion remained morphologically stable. The intermediate small lesion also showed morphological regression on CT (Figure 1A′,B′); however, its physiological significance was not assessed and no functional inference is made. Follow‐up FFR pullback at 2 years mirrored these findings: distal LAD FFR improved from 0.50 to 0.75, rising to 0.95 across the distal lesion (ΔFFR + 0.20) and 0.97 across the proximal lesion (ΔFFR + 0.02), indicating that the improvement was driven mainly by attenuation of the proximal lesion's ΔFFR contribution (Figure 1E′). The patient remained asymptomatic, with cardiopulmonary exercise testing showing preserved exercise capacity to 12 METs without evidence of ischemia.
A timeline of the clinical course is summarized as follows: intensive lipid‐lowering therapy was initiated at baseline, with a reduction of LDL‐C from 86 mg/dL to < 35 mg/dL observed within 5 months. Serial coronary CT angiography and intravascular ultrasound performed at 1 and 2 years demonstrated progressive regression of the proximal lipid‐rich plaque. Follow‐up FFR pullback assessment at 2 years confirmed corresponding lesion‐specific physiological improvement.
3. Discussion
This case demonstrates that plaque morphology critically influences the response to intensive lipid‐lowering therapy within the same patient and the same coronary vessel. Specifically, tandem LAD plaques with distinct phenotypes exhibited divergent anatomic and physiological responses despite identical systemic lipid lowering. The markedly abnormal baseline FFR of 0.50 reflected the combined contribution of both the distal fibrous and proximal lipid‐rich LAD lesions (Figure 1E). During follow‐up, the proximal lesion underwent dramatic regression and stabilization, with reduction in ΔFFR from +0.20 to +0.02, whereas the distal fibrous lesion remained morphologically and functionally stable (ΔFFR baseline +0.23, follow‐up +0.20) (Figure 1C′–E′). An additional small intermediate lesion also showed regression on serial CT (Figure 1A′,B′), although no functional assessment was performed.
Importantly, the patient's baseline LDL‐C level was already near guideline‐recommended targets at presentation; however, a single measurement may not reflect prior lipid exposure, particularly in the setting of suboptimal medication adherence. Accordingly, the presence of significant obstructive coronary disease cannot be explained by baseline LDL‐C alone.
The observed differential plaque response is therefore likely multifactorial. While intensive lipid‐lowering therapy appears to have contributed to regression of the lipid‐rich plaque, our findings are best interpreted as demonstrating a morphology‐dependent response to therapy rather than a direct causal relationship between baseline LDL‐C and plaque burden. Given the observational nature of this single‐patient case and concomitant therapies, these findings should be interpreted as associations rather than evidence of a direct causal effect.
The preferential response of lipid‐rich plaques to intensive lipid‐lowering therapy has been well documented in prior imaging studies. Trials such as ASTEROID and SATURN demonstrated that aggressive statin therapy is associated with greater regression of atheroma volume, particularly in lipid‐rich plaques, accompanied by reductions in lipid core size and features of plaque stabilization [3, 4], while the GLAGOV trial further showed incremental atheroma regression with more intensive LDL‐C lowering [7]. Similarly, the YELLOW study showed rapid depletion of lipid content and improvement in lesion physiology following intensive statin therapy [8]. In contrast, fibrous‐predominant plaques, characterized by lower lipid burden, typically exhibit limited anatomic remodeling despite optimized lipid‐lowering therapy.
From a physiological perspective, improvements in lesion‐specific FFR have been linked to reductions in ischemic burden and more favorable clinical profiles. In the present case, regression of the proximal lipid‐rich plaque was accompanied by a marked reduction in its ΔFFR contribution, whereas the distal fibrous lesion continued to impose a persistent physiological gradient. Although FFR remains a surrogate marker, the concordance between morphology‐specific plaque regression, physiological improvement, and symptom resolution underscores the clinical relevance of morphology‐dependent therapeutic responses.
Figure 2 further quantifies these findings. Panel A demonstrates sustained LDL‐C suppression from a baseline level of 86 mg/dL to < 35 mg/dL (> 60% reduction) throughout follow‐up under intensive statin and ezetimibe therapy. Panel B summarizes lesion‐specific ΔFFR contributions: at baseline, both proximal and distal lesions contributed significantly to the overall ischemia, but after 2 years, only the distal lesion remained physiologically relevant. These multimodality imaging and physiological data emphasize that global LDL‐C lowering is an important component of therapy. However, the degree of anatomic regression and functional improvement depends critically on plaque morphology.
Our observations are consistent with prior studies. The PROSPECT trial demonstrated that lipid‐rich plaques are associated with higher event risk, whereas fibrous‐predominant plaques are more stable [1]. Imaging trials such as ASTEROID and SATURN confirmed that high‐intensity statin therapy induces greater regression in lipid‐rich than fibrous plaques [3, 4]. OCT and IVUS studies have documented fibrous cap thickening and plaque stabilization during lipid‐lowering therapy [5], while ISCHEMIA and REVIVED‐BCIS2 showed that in patients with stable coronary artery disease, optimized medical therapy is not inferior to early revascularization in outcomes [9, 10]. Furthermore, NIRS‐IVUS registries have highlighted that lipid‐rich plaques are not only higher risk but also more responsive to LDL‐C reduction [11].
Taken together, this case supports two important, hypothesis‐generating implications. First, guideline‐directed medical therapy, when aligned with patient preference, was associated with substantial plaque regression and lesion‐specific physiological changes (i.e., attenuation of lesion‐specific ΔFFR contribution on pullback) in a lesion with markedly abnormal baseline FFR. Second, regression was not uniform across all lesions: lipid‐rich plaques may show pronounced anatomic change, whereas fibrous‐predominant plaques may persist morphologically and physiologically despite optimized therapy. Given that the comparison is based on two functionally assessed lesions in a single patient, other local factors (e.g., lesion location, baseline plaque burden, remodeling, and hemodynamic/microvascular variability) may also have contributed to the differential response.
4. Conclusion
In a patient with stable angina, this case illustrates morphology‐dependent differences in plaque regression and lesion‐specific physiology within the same coronary vessel during intensive lipid‐lowering therapy. Multimodality imaging with lesion‐specific physiological assessment showed marked improvement in a lipid‐rich plaque and persistence of a fibrous lesion; these observations should be considered hypothesis‐generating.
1. Conflicts of Interest
The authors declare no conflicts of interest.
Acknowledgments
This work was supported by the 2025 New Faculty Research Support Grant from Gyeongsang National University (GNU‐NFRSG‐0030).
Data Availability Statement
All data are available upon reasonable request to the corresponding author.
References
- 1. Stone G. W., Maehara A., Lansky A. J., et al., “A Prospective Natural‐History Study of Coronary Atherosclerosis,” New England Journal of Medicine 364, no. 3 (2011): 226–235. [DOI] [PubMed] [Google Scholar]
- 2. Ridker P. M., Danielson E., Fonseca F. A. H., et al., “Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C‐Reactive Protein,” New England Journal of Medicine 359, no. 21 (2008): 2195–2207. [DOI] [PubMed] [Google Scholar]
- 3. Nissen S. E., Nicholls S. J., Sipahi I., et al., “Effect of Very High‐Intensity Statin Therapy on Regression of Coronary Atherosclerosis: The ASTEROID Trial,” Journal of the American Medical Association 295, no. 13 (2006): 1556–1565. [DOI] [PubMed] [Google Scholar]
- 4. Nicholls S. J., Ballantyne C. M., Barter P. J., et al., “Effect of Two Intensive Statin Regimens on Progression of Coronary Disease,” New England Journal of Medicine 365, no. 22 (2011): 2078–2087. [DOI] [PubMed] [Google Scholar]
- 5. Kataoka Y., Puri R., Hammadah M., et al., “Plaque Microstructures in Patients With Coronary Artery Disease Treated With Intensive Statin Therapy: Serial OCT Analysis,” JACC Cardiovasc Imaging 9, no. 6 (2016): 627–636.26189122 [Google Scholar]
- 6. Koo B. K., Erglis A., Doh J. H., et al., “Diagnosis of Ischemia‐Causing Coronary Stenoses by Noninvasive Fractional Flow Reserve Computed From Coronary Computed Tomographic Angiograms,” Journal of the American College of Cardiology 58, no. 19 (2011): 1989–1997. [DOI] [PubMed] [Google Scholar]
- 7. Nicholls S. J., Puri R., Anderson T., et al., “Effect of Evolocumab on Progression of Coronary Disease in Statin‐Treated Patients: The GLAGOV Randomized Clinical Trial,” Journal of the American Medical Association 316 (2016): 2373–2384. [DOI] [PubMed] [Google Scholar]
- 8. Kini A. S., Baber U., Kovacic J. C., et al., “Changes in Plaque Lipid Content After Short‐Term Intensive Versus Standard Statin Therapy,” Journal of the American College of Cardiology 62 (2013): 21–29. [DOI] [PubMed] [Google Scholar]
- 9. Maron D. J., Hochman J. S., Reynolds H. R., et al., “Initial Invasive or Conservative Strategy for Stable Coronary Disease,” New England Journal of Medicine 382, no. 15 (2020): 1395–1407. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Perera D., Clayton T., O'Kane P. D., et al., “Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction,” New England Journal of Medicine 387, no. 16 (2022): 1351–1360. [DOI] [PubMed] [Google Scholar]
- 11. Oemrawsingh R. M., Cheng J. M., García‐García H. M., et al., “Near‐Infrared Spectroscopy Predicts Cardiovascular Outcome in Patients With Coronary Artery Disease,” Journal of the American College of Cardiology 64, no. 23 (2014): 2510–2518. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All data are available upon reasonable request to the corresponding author.
